Italian-led Ivermectin Meta-Analysis: Is it Time to Consider the Generic Low Cost Option to Help Treat COVID-19?
A group of six critical care physicians and researchers, four of who are affiliated with IRCCS (IRCCS Ospedale San Raffaele) San Raffaele Scientific Institute in Milan, Italy, recently conducted a meta-analysis looking into ivermectin and along the way asking a highly uncomfortable question as to whether suspect claims about safety for commonly available drugs in fact are driven by a deep-seated, intensive fear of failure among the scientific and medical community. The idea that, with tens of billions have been invested into a particular approach, anything that gets in the way could be deemed recognition of failure.
Emory Discovered Drug May Take Over $3+ Billion Market Now Going to Remdesivir:
EIDD-2801, the Merck drug now known as Molnupiravir, can be administered orally as a pill in an outpatient setting. Now, as we have identified here at TrialSite News, The big gap drug companies have yet to fill with regards to COVID-19 is treatment at early onset of the SARS-CoV-2 virus, during the mild to moderate stage. Instead, what most commonly happens today, is folks diagnosed positive are often simply sent home most of the time with no treatment.